|
|
 Tuesday, January 05, 2010 / Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD.Tuesday, October 20, 2009 / Oraya Therapeutics to present at Ophthalmology Innovations Summit The Ophthalmology Innovation Summit (OIS), to be held at the Palace Hotel in San Francisco on October 22, 2009, will bring together leaders in the development of ophthalmic products, drugs, and devices. Oraya therapeutics will present a summary of its innovative technology, currently undergoing clinical evaluation for the treatment of wet macular degeneration. Additional information can be found at http://www.ophthalmologysummit.com.Tuesday, August 04, 2009 / Oraya Therapeutics Names JIM TAYLOR as President and Chief Executive Officer Appointment of seasoned executive will support development of company's age-related macular degeneration treatmentMonday, July 20, 2009 / Oraya Therapeutics Raises $42 MILLION in Series C Financing Company to begin international multi-center clinical trials for age-related macular degeneration treatment |
Copyright © 2009 Oraya Therapeutics, Inc. All rights reserved. | (510) 456-3700 | info@orayainc.com
Note: IRay™ is an investigational device. Limited by Federal (U.S.A.) law to investigational use.
Note: IRay™ is an investigational device. Limited by Federal (U.S.A.) law to investigational use.